Harvard University

Symetra Appoints Soraya Alexander and April Galda Joyce to Board of Directors

Retrieved on: 
Thursday, April 4, 2024
Professional Services, Insurance, Human Resources, Finance, Growth, Reinsurance, Goldman Sachs, Risk, Case Western Reserve University, Harvard University, Harvard Business School, Acquisition, University, MBA, GoFundMe, Multimedia, Marketing, Data management, Engineering, MGA, Management

Symetra Financial Corporation today announced the appointments of Soraya Alexander and April Galda Joyce to its board of directors.

Key Points: 
  • Symetra Financial Corporation today announced the appointments of Soraya Alexander and April Galda Joyce to its board of directors.
  • View the full release here: https://www.businesswire.com/news/home/20240404333545/en/
    Soraya Alexander joins Symetra Financial Corporation's board of directors.
  • (Photo: Business Wire)
    “We are very pleased to welcome Soraya and April to the Symetra board.
  • Ms. Galda Joyce received a Bachelor of Science in management from Case Western Reserve University.

JDRF T1D Fund, a Leading Disease-Focused Venture Philanthropy Fund, Appoints Sylvia Tobé as Managing Director

Retrieved on: 
Wednesday, April 3, 2024
Genetics, Diabetes, Philanthropy, Other Health, Biotechnology, Fund Raising, Pharmaceutical, Health, Foundation, Other Philanthropy, Neurology, Growth, Synthetic biology, T1D, Merck, University, Doctor of Philosophy, Investment, Harvard University, Autoimmune disease, Pharmaceutical industry

The JDRF T1D Fund, a venture philanthropy investment fund focused on curing type 1 diabetes (T1D), announced today that Sylvia Tobé, PhD had joined as a Managing Director based in Boston.

Key Points: 
  • The JDRF T1D Fund, a venture philanthropy investment fund focused on curing type 1 diabetes (T1D), announced today that Sylvia Tobé, PhD had joined as a Managing Director based in Boston.
  • Dr. Tobé will work alongside the T1D Fund’s other Managing Directors and members of the investment team to advance and broaden the T1D Fund's investment activities and capabilities.
  • Dr. Tobé has a decade of life sciences industry experience and joins from Omega Funds, where she served as a Principal on the investment team.
  • Dr. Tobé also provided scientific leadership for multiple discovery programs within the company's internal pipeline and in collaboration with Merck.

Nimble Therapeutics Expands its Drug Discovery Capabilities to Advance Pipeline to the Clinic

Retrieved on: 
Wednesday, April 3, 2024
Oncology, Health, Infectious Diseases, Radiology, Pharmaceutical, Biotechnology, Pfizer, De Montfort University, Drug discovery, Yale University, BU, Harvard University, Patient, Flavell, Immunology, Merck, Head, Wetzler, Merck & Co., IND, Rhône-Poulenc, Therapy, CSO, American Chemical Society, Medicinal chemistry, Peptide, Pharmaceutical industry

In addition to the new site, Nimble also announced the appointment of two senior leaders to spearhead the drug discovery efforts and catalyze the build out of the Philadelphia site and team.

Key Points: 
  • In addition to the new site, Nimble also announced the appointment of two senior leaders to spearhead the drug discovery efforts and catalyze the build out of the Philadelphia site and team.
  • Shelley Allen will join as Head of Drug Discovery and will lead the advanced optimization and characterization of clinical candidate peptides and their progression into the clinic.
  • Munir Mosaheb will join as Head of Biology and will lead the pharmacological, immunological and translational aspects of Nimble’s drug discovery programs.
  • She joined Nimble from Think Bioscience where she was VP, Medicinal Chemistry, and responsible for establishing drug discovery teams and capabilities to develop their internal programs.

Ellie McDonald and Jeannine Sargent Join G2 Venture Partners

Retrieved on: 
Wednesday, April 3, 2024
Environment, Climate Change, Finance, Professional Services, Business, Sustainability, Alternative Energy, Green Technology, Start-Up, Energy, Research, Flex, TEL Solar, Fortive, Growth, Princeton University, Synopsys, MIT, University, Harvard University, Climate, Operations research, Stanford University, MSIP, Investment, Chemical engineering, G2, Engineering, Power, Barclays, Renewable energy

G2 Venture Partners , a venture capital firm investing in transformative technology companies at their inflection points to build a sustainable future, today announced that Ellie McDonald and Jeannine Sargent have joined the firm.

Key Points: 
  • G2 Venture Partners , a venture capital firm investing in transformative technology companies at their inflection points to build a sustainable future, today announced that Ellie McDonald and Jeannine Sargent have joined the firm.
  • Ellie McDonald joins G2 Venture Partners as an Investor, having spent the past seven years working across investment and engineering disciplines.
  • Prior to joining G2, Ellie was a Private Equity Associate at Morgan Stanley Infrastructure Partners (MSIP), primarily investing in the energy and telecommunication sectors.
  • “We are thrilled to welcome the unique perspectives and deep experience that both Ellie and Jeannine bring to our talented team,” said Brook Porter, Founding Partner at G2.

Brightly Expands Leadership Team

Retrieved on: 
Friday, March 29, 2024
Software, Professional Services, Internet, Data Management, IOT (Internet of Things), Technology, Digital Cash Management, Digital Assets, Asset Management, Data Analytics, Other Professional Services, Human Resources, Other Technology, Consulting, Culture, Organization, Siemens EDA, Growth, Acquisition, Siemens Digital Industries Software, Hughes, City, Harvard University, Engle, Workplace, Engineering

“Nigel and Christine bring years of strong experience at the global level to their respective fields, and we’re pleased to welcome them to Brightly as we continue our growth,” said Kevin Kemmerer, chief executive officer at Brightly.

Key Points: 
  • “Nigel and Christine bring years of strong experience at the global level to their respective fields, and we’re pleased to welcome them to Brightly as we continue our growth,” said Kevin Kemmerer, chief executive officer at Brightly.
  • She joins Brightly from Maersk, Inc. where she served in many different functions, most recently as the global head of business performance for M&A.
  • “I’m thrilled to join Brightly and look forward to continuing to build on the company’s strong culture,” said Christine Engle, senior vice president, P&O.
  • “Since the acquisition by Siemens Smart Infrastructure in 2022, I’ve seen firsthand how Brightly puts their clients at the center of product innovation and I look forward to continuing this mission,” said Nigel Hughes, head of product at Brightly.

Kelonia Therapeutics Appoints Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to Board of Directors

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Harvard Medical School, Flexner Report, Organization, Bone marrow, Internal medicine, UCSF, Hematology, Science, HST, Massachusetts Institute of Technology, BCMA, Patient, HIV, Dartmouth College, BMS, Cancer, Bristol Myers Squibb, Doctor of Philosophy, Daratumumab, Biochemistry, Chemistry, Therapy, Harvard University, Hospital, Johnson & Johnson, Drug development, FDA, Pharmaceutical industry

Kelonia Therapeutics , a biotech company revolutionizing in vivo gene delivery, today announced the appointments of global leaders in cell therapy and drug development, Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors.

Key Points: 
  • Kelonia Therapeutics , a biotech company revolutionizing in vivo gene delivery, today announced the appointments of global leaders in cell therapy and drug development, Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors.
  • Furthermore, some patients never receive their autologous CAR-T products due to disease progression or clinical deterioration during the manufacturing window.
  • In addition, the field of cell and gene therapy has gained tremendous expertise and insight into the manufacturing of lentiviral vectors at commercial scale.
  • from the Harvard Medical School and Massachusetts Institute of Technology (HST) and a Ph.D. in chemistry from Harvard University.

NTT Research PHI Lab Scientists Achieve Quantum Control of Excitons in 2D Semiconductors

Retrieved on: 
Tuesday, March 26, 2024
Semiconductor, Technology, Nanotechnology, Telecommunications, Other Science, Research, Science, ETH Zurich, Photon, Physics, University of Notre Dame, Logic, 2D, CMOS, Quantum, PHI, MIT, Cornell University, Ames Research Center, Swinburne University of Technology, Light, University, Nature, Nobel Prize, Architecture, Silicon, NASA, Harvard University, NTT, Stanford University, CIM, Ising, Quantum dot, Engineering, Microscope

NTT Research, Inc. , a division of NTT (TYO:9432), today announced that scientists from its Physics & Informatics (PHI) Lab have achieved quantum control of exciton wavefunctions in two-dimensional (2D) semiconductors.

Key Points: 
  • NTT Research, Inc. , a division of NTT (TYO:9432), today announced that scientists from its Physics & Informatics (PHI) Lab have achieved quantum control of exciton wavefunctions in two-dimensional (2D) semiconductors.
  • However, achieving fine control over their quantum mechanical state has been plagued with scalability issues due to limitations in existing fabrication techniques.
  • In particular, the control over position and energy of quantum dots has been a major hindrance to scaling up towards quantum applications.
  • The PHI Lab has also entered a joint research agreement with the NASA Ames Research Center in Silicon Valley.

Hume AI Announces $50 Million Fundraise and Empathic Voice Interface

Retrieved on: 
Wednesday, March 27, 2024
Apps, Applications, Technology, Research, Health Technology, Health, General Health, Other Science, Science, Artificial Intelligence, Comcast Ventures, Speech, Union Square Ventures, Face, Communication, Cognitive science, Intelligence, Harvard University, Trends in Cognitive Sciences, Knowledge, Artificial intelligence, Nature, AI, SoftBank Group, EVI, Robotics, Happiness, API, Emotion, EQT Ventures, Human, Customer service

Hume AI (“Hume” or the “Company”), a startup and research lab building artificial intelligence optimized for human well-being, today announced it has raised a $50M Series B.

Key Points: 
  • Hume AI (“Hume” or the “Company”), a startup and research lab building artificial intelligence optimized for human well-being, today announced it has raised a $50M Series B.
  • In connection with the fundraise, Hume AI has released a beta version of its flagship product, an Empathic Voice Interface (EVI).
  • With a single API call, developers can integrate EVI into any application to create state-of-the-art voice AI experiences.
  • Sinai have demonstrated.”
    The growing Hume AI team currently comprises 35 leading researchers, engineers, and scientists advancing Dr. Cowen’s work on semantic space theory.

Ivy Fertility Hires Dr. Bryn Willson and Dr. Shelun Tsai

Retrieved on: 
Thursday, March 21, 2024
Baby, Maternity, Managed Care, Other Health, Health, Women, Other Science, Research, Hospitals, Genetics, Consumer, Science, Cedars-Sinai Medical Center, Education, Weill Cornell Medicine, SDFC, Patient, Duke University, UC, University, Weill Cornell Medical Center, MD, Pacific coast, Infertility, Gynaecology, Harvard University, University of California, Davis, Santa Clara University, Golden apple, Obstetrics, Duke, Physician, Hedera

Ivy Fertility, a collaborative network of globally-renowned fertility clinics, is thrilled to welcome Bryn Willson, MD and Shelun Tsai, MD to its collaborative team of physicians.

Key Points: 
  • Ivy Fertility, a collaborative network of globally-renowned fertility clinics, is thrilled to welcome Bryn Willson, MD and Shelun Tsai, MD to its collaborative team of physicians.
  • Dr. Willson and Dr. Tsai are both board-certified in obstetrics and gynecology, and will complete their fellowships in reproductive endocrinology this spring.
  • “The entire Ivy Fertility network is committed to staying at the forefront of fertility science,” said Sandy Chuan, MD, Medical Director at San Diego Fertility Center.
  • “We are privileged that Dr. Willson and Dr. Tsai will be contributing their innovation and compassion to our network.”

Centerville City Schools TWO YEARS AHEAD of National Average in Math

Retrieved on: 
Tuesday, March 19, 2024
Software, Other Education, Artificial Intelligence, Technology, Philanthropy, Primary, Secondary, Education, Foundation, Learning, The New York Times, Harvard University, School, Portrait, Stanford University, Student, Carnegie Learning, Mathematics, Curriculum, Multimedia, Tutoring

While the majority of schools across America are facing daunting learning losses, particularly in mathematics, Centerville City Schools are flipping the script.

Key Points: 
  • While the majority of schools across America are facing daunting learning losses, particularly in mathematics, Centerville City Schools are flipping the script.
  • In fact, Centerville students in grades 3-8 are improving twice as fast as the rest of the nation in math, despite the pandemic.
  • View the full release here: https://www.businesswire.com/news/home/20240319860334/en/
    Centerville City Schools student math performance exceeded pre-pandemic levels, putting the Ohio district 2 years ahead of the national average using Carnegie Learning's math curriculum.
  • We’re proud to have the opportunity to collaborate with Centerville City Schools to help students succeed.”